Duloxetine
Product Images NDC 43063-877

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 43063-877). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (43063877)

Label for Duloxetine DR USP 30 mg capsules, containing 90 capsules, from PD-Rx Pharmaceuticals, Inc. The label includes the NDC 43063-877-90, lot number D22A11, and expiration date 04/2023. It displays dosage and storage warnings, reorder number, and pharmacy use information along with a barcode and QR code.*

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A Kaplan-Meier survival curve comparing the proportion of patients with relapse over time (days) between those treated with Duloxetine and placebo. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The Duloxetine group has a consistently lower relapse proportion than the placebo group over the observed period.*

FDA Label Image

Fig2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time (days) for two treatments: placebo and duloxetine. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients experiencing relapse. The plot indicates differences in relapse rates between the two groups over approximately 270 days.*

FDA Label Image

Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)

A line graph depicting the percentage of patients improved in pain from baseline against percent improvement in pain. Four different treatments are compared: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph shows trends over varying percentages of improvement.*

FDA Label Image

Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline. It includes data lines for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, showing patient improvement trends across varying pain improvement percentages.*

FDA Label Image

Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. The graph includes three lines representing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing trends in patient improvement across varying pain reduction levels.*

FDA Label Image

Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Duloxetine at 20 mg, 60 mg, and 120 mg once daily doses compared to placebo. The graph shows four lines representing each group, illustrating patient improvement distribution across different percentages of pain improvement.*

FDA Label Image

Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The vertical axis shows percentage of patients improved, and the horizontal axis shows percent improvement in pain from baseline, with plotted lines indicating treatment outcomes.*

FDA Label Image

Duloxetine Fig8

A line graph comparing percentage improvement in pain from baseline between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain, and the y-axis shows percentage of patients improved. Duloxetine consistently shows higher patient improvement percentages than placebo across increasing levels of pain improvement.*

FDA Label Image

Duloxetine Fig9

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The graph shows two lines with markers indicating patient improvement over a range of pain improvement percentages.*

FDA Label Image

Structure (Duloxetine Str)

Chemical structure diagram of duloxetine hydrochloride showing its molecular framework including aromatic rings and functional groups clearly labeled.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.